HUP0501025A2 - Substituted phenyl naphthalenes as estrogenic agents and their use - Google Patents
Substituted phenyl naphthalenes as estrogenic agents and their useInfo
- Publication number
- HUP0501025A2 HUP0501025A2 HU0501025A HUP0501025A HUP0501025A2 HU P0501025 A2 HUP0501025 A2 HU P0501025A2 HU 0501025 A HU0501025 A HU 0501025A HU P0501025 A HUP0501025 A HU P0501025A HU P0501025 A2 HUP0501025 A2 HU P0501025A2
- Authority
- HU
- Hungary
- Prior art keywords
- substituted phenyl
- estrogenic agents
- naphthalenes
- phenyl naphthalenes
- estrogenic
- Prior art date
Links
- IYDMICQAKLQHLA-UHFFFAOYSA-N 1-phenylnaphthalene Chemical class C1=CC=CC=C1C1=CC=CC2=CC=CC=C12 IYDMICQAKLQHLA-UHFFFAOYSA-N 0.000 title 1
- 239000000262 estrogen Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/24—Halogenated derivatives
- C07C39/38—Halogenated derivatives with at least one hydroxy group on a condensed ring system containing two rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A61K31/055—Phenols the aromatic ring being substituted by halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/13—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups
- C07C205/20—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings
- C07C205/25—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings having nitro groups bound to carbon atoms of six-membered aromatic rings being part of a condensed ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/13—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups
- C07C205/26—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups and being further substituted by halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/53—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/12—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
- C07C39/14—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings with at least one hydroxy group on a condensed ring system containing two rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/12—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
- C07C39/15—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings with all hydroxy groups on non-condensed rings, e.g. phenylphenol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
- C07C49/747—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups containing six-membered aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34116401P | 2001-12-13 | 2001-12-13 | |
PCT/US2002/039883 WO2003051805A2 (en) | 2001-12-13 | 2002-12-12 | Substituted phenyl naphthalenes as estrogenic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
HUP0501025A2 true HUP0501025A2 (en) | 2006-03-28 |
Family
ID=23336481
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0501025A HUP0501025A2 (en) | 2001-12-13 | 2002-12-12 | Substituted phenyl naphthalenes as estrogenic agents and their use |
Country Status (18)
Country | Link |
---|---|
US (2) | US6914074B2 (hu) |
EP (1) | EP1453782A2 (hu) |
JP (1) | JP4566561B2 (hu) |
KR (1) | KR20040071197A (hu) |
CN (1) | CN1738788A (hu) |
AR (1) | AR038019A1 (hu) |
AU (2) | AU2002361659A1 (hu) |
BR (1) | BR0215042A (hu) |
CA (1) | CA2470109C (hu) |
HU (1) | HUP0501025A2 (hu) |
IL (1) | IL161740A0 (hu) |
MX (1) | MXPA04005629A (hu) |
NO (1) | NO20042955L (hu) |
PL (1) | PL374300A1 (hu) |
RU (2) | RU2314283C2 (hu) |
TW (1) | TWI306450B (hu) |
WO (1) | WO2003051805A2 (hu) |
ZA (1) | ZA200405512B (hu) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003044006A1 (en) | 2001-11-19 | 2003-05-30 | Eli Lilly And Company | Substituted benzopyrans as selective estrogen receptor-beta agonists |
TWI306450B (en) * | 2001-12-13 | 2009-02-21 | Wyeth Corp | Substituted phenyl naphthalenes as estrogenic agents |
WO2004094400A2 (en) | 2003-04-21 | 2004-11-04 | Eli Lilly And Company | Substituted benzopyrans as selective estrogen receptor-beta agonists |
US7279499B2 (en) | 2003-04-21 | 2007-10-09 | Eli Lilly And Company | Substituted benzopyrans as selective estrogen receptor-beta agonists |
CL2004000985A1 (es) | 2003-05-16 | 2005-01-14 | Wyeth Corp | Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc |
TW200500065A (en) * | 2003-05-21 | 2005-01-01 | Wyeth Corp | Antiarthritic combinations |
US7557237B2 (en) * | 2003-09-09 | 2009-07-07 | Wyeth | Process for the synthesis of 3-(3-fluoro-4-hydroxyphenyl)-7-hydroxynaphthonitrile |
US7196119B2 (en) | 2003-10-21 | 2007-03-27 | The Regents Of The University Of California | Development of new selective estrogen receptor modulators |
EP1704856A4 (en) * | 2003-12-26 | 2009-08-19 | Kyowa Hakko Kirin Co Ltd | PROTEIN INHIBITOR OF THE HSP90 FAMILY |
US7157492B2 (en) * | 2004-02-26 | 2007-01-02 | Wyeth | Dibenzo chromene derivatives and their use as ERβ selective ligands |
US7425580B2 (en) | 2004-05-19 | 2008-09-16 | Wyeth | (Diaryl-methyl)-malononitriles and their use as estrogen receptor ligands |
JP2008505095A (ja) * | 2004-07-01 | 2008-02-21 | ワイス | エストロゲンリガンドとしての四環式化合物 |
US7145040B2 (en) * | 2004-07-02 | 2006-12-05 | Bristol-Myers Squibb Co. | Process for the preparation of amino acids useful in the preparation of peptide receptor modulators |
KR20070086329A (ko) * | 2004-12-17 | 2007-08-27 | 와이어쓰 | 에스트로겐 베타 아고니스트의 신규 용도 |
CA2593097A1 (en) * | 2004-12-31 | 2006-07-13 | Aventis Pharmaceuticals Inc. | Use of certain phenyl-naphthyl compounds that do not have significant affintiy to er alpha or beta for protection of neurons and oligodendrocytes in the treatment of multiple sclerosis |
JP2008526744A (ja) * | 2005-01-04 | 2008-07-24 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | 多発性硬化症(ms)の治療における神経細胞及び乏突起膠細胞を保護するための或る種のフェニルナフチル化合物の使用 |
GT200600064A (es) * | 2005-02-16 | 2006-11-09 | Uso de agonistas selectivos para el receptor-b de estrogeno para la mucositis inducida por radiación o por quimioterapia y para la cistitis inducida por radiación | |
EP1702558A1 (en) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Method and device for the assessment of bowel function |
EP1853261B1 (de) | 2005-03-03 | 2017-01-11 | Universität des Saarlandes | Selektive hemmstoffe humaner corticoidsynthasen |
EP1984028A2 (en) * | 2006-02-14 | 2008-10-29 | Wyeth a Corporation of the State of Delaware | Aqueous pharmaceutical formulations of er selective ligands |
US9604931B2 (en) | 2007-01-22 | 2017-03-28 | Gtx, Inc. | Nuclear receptor binding agents |
US9623021B2 (en) * | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
MX2009007831A (es) | 2007-01-22 | 2010-01-15 | Gtx Inc | Agentes de union de receptor nuclear. |
CN101600421A (zh) * | 2007-01-31 | 2009-12-09 | 惠氏公司 | 雌激素受体β选择性配体用于治疗急性肺损伤的用途 |
AR065399A1 (es) * | 2007-02-21 | 2009-06-03 | Wyeth Corp | Mono- y di- fosfatos de 3- (3-fluoro-4-hidroxi-fenil) -7-hidroxi-naftalen-1-carbonitrilo |
DE102007015169A1 (de) | 2007-03-27 | 2008-10-02 | Universität des Saarlandes Campus Saarbrücken | 17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen |
EP2144916A4 (en) * | 2007-04-10 | 2012-01-04 | Univ Pennsylvania | PHENYLNAPHTHALENE DERIVATIVES AND PHENYLQUINOLINES AND THEIR USE FOR THE BINDING AND FORMATION OF AMYLOID PLATE IMAGES |
KR101101977B1 (ko) * | 2009-04-09 | 2012-01-02 | (주)에스메디 | 2-아릴나프탈렌, 2-아릴퀴놀린 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물 |
CA2760526A1 (en) | 2009-04-30 | 2010-11-04 | Rutgers, The State University Of New Jersey | Antimicrobial agents |
US9102617B2 (en) * | 2010-06-25 | 2015-08-11 | Rutgers, The State University Of New Jersey | Antimicrobial agents |
WO2013048145A2 (ko) * | 2011-09-30 | 2013-04-04 | 부산대학교 산학협력단 | 6-(3-하이드록시페닐)-2-나프톨 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 염증성 질환 또는 골량 저하 관련 질환의 예방 또는 치료용 조성물 |
WO2013106756A2 (en) | 2012-01-13 | 2013-07-18 | Rutgers, The State University Of New Jersey | Antimicrobial agents |
EP2828245A1 (en) | 2012-03-21 | 2015-01-28 | Rutgers, The State University of New Jersey | Antimicrobial agents |
CN102675056A (zh) * | 2012-05-24 | 2012-09-19 | 盛世泰科生物医药技术(苏州)有限公司 | 一种6-溴-8-氟-2-萘酚的制备方法 |
CN103193601A (zh) * | 2013-04-11 | 2013-07-10 | 山东大学 | 2-苯基萘衍生物及其在制备抗肿瘤药物中的应用 |
US9458150B2 (en) | 2013-11-08 | 2016-10-04 | Rutgers, The State University Of New Jersey | Antimicrobial agents |
US10385034B2 (en) | 2014-09-05 | 2019-08-20 | The Cleveland Clinic Foundation | Flavonoid IL-17A inhibitors |
WO2017120507A1 (en) * | 2016-01-06 | 2017-07-13 | The Board Of Trustees Of The University Of Illinois | Novel compounds which activate estrogen receptors and compositions and methods of using the same |
CA3015768A1 (en) | 2016-02-25 | 2017-08-31 | Taxis Pharmaceuticals, Inc. | Synthetic processes and intermediates |
CN110891566B (zh) | 2017-03-30 | 2023-12-19 | 塔克西斯医药股份有限公司 | 合成方法和合成中间体 |
CN107474038B (zh) * | 2017-07-17 | 2020-10-09 | 苏州楚凯药业有限公司 | 一类靶向雌激素受体荧光探针及其制备和使用方法 |
EP4036189A1 (en) * | 2021-02-02 | 2022-08-03 | Indian Oil Corporation Limited | Process for synthesis of polyhydrocarbons as heat transfer agents |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8410901D0 (en) * | 1984-04-27 | 1984-06-06 | Ici Plc | Phenol derivatives |
IE58417B1 (en) * | 1984-04-27 | 1993-09-22 | Ici Plc | Chemical derivatives |
LU85849A1 (fr) * | 1985-04-11 | 1986-11-05 | Cird | Derives benzonaphtaleniques,leur procede de preparation et leur application dans les domaines pharmaceutiques et cosmetiques |
FR2676052B1 (fr) | 1991-05-02 | 1994-04-29 | Cird Galderma | Nouveaux composes polycycliques aromatiques et leur utilisation en medecine humaine ou veterinaire et en cosmetique. |
DK77393D0 (da) | 1993-06-29 | 1993-06-29 | Novo Nordisk As | Aktivering af enzymer |
US5998401A (en) | 1995-02-28 | 1999-12-07 | Eli Lilly And Company | Naphthyl compounds, intermediates, compositions, and methods |
US6448294B1 (en) * | 1996-02-01 | 2002-09-10 | Aventis Pharma S.A. | Biphenyl compounds and their use as oestrogenic agents |
FR2744444B1 (fr) * | 1996-02-01 | 1998-05-29 | Roussel Uclaf | Nouveaux composes biphenyles, procede et intermediaires de preparation, application a titre de medicaments et compositions pharmaceutiques les renfermant |
FR2747041B1 (fr) * | 1996-04-05 | 1998-05-22 | Cird Galderma | Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies |
US5916916A (en) * | 1996-10-10 | 1999-06-29 | Eli Lilly And Company | 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods |
IL145839A0 (en) * | 1999-04-16 | 2002-07-25 | Astrazeneca Ab | ESTROGEN RECEPTOR-β LIGANDS |
AU780947B2 (en) | 1999-12-13 | 2005-04-28 | Chugai Seiyaku Kabushiki Kaisha | Compound having hydroxycarbonyl-halogenoalkyl side chain |
TWI306450B (en) * | 2001-12-13 | 2009-02-21 | Wyeth Corp | Substituted phenyl naphthalenes as estrogenic agents |
-
2002
- 2002-12-11 TW TW091135871A patent/TWI306450B/zh not_active IP Right Cessation
- 2002-12-11 US US10/316,640 patent/US6914074B2/en not_active Expired - Fee Related
- 2002-12-12 CN CNA028247361A patent/CN1738788A/zh active Pending
- 2002-12-12 EP EP02797299A patent/EP1453782A2/en not_active Withdrawn
- 2002-12-12 RU RU2004121227/04A patent/RU2314283C2/ru not_active Application Discontinuation
- 2002-12-12 PL PL02374300A patent/PL374300A1/xx unknown
- 2002-12-12 IL IL16174002A patent/IL161740A0/xx unknown
- 2002-12-12 CA CA2470109A patent/CA2470109C/en not_active Expired - Fee Related
- 2002-12-12 HU HU0501025A patent/HUP0501025A2/hu unknown
- 2002-12-12 AR ARP020104829A patent/AR038019A1/es unknown
- 2002-12-12 WO PCT/US2002/039883 patent/WO2003051805A2/en active Application Filing
- 2002-12-12 KR KR10-2004-7009120A patent/KR20040071197A/ko not_active Application Discontinuation
- 2002-12-12 MX MXPA04005629A patent/MXPA04005629A/es active IP Right Grant
- 2002-12-12 JP JP2003552695A patent/JP4566561B2/ja not_active Expired - Fee Related
- 2002-12-12 AU AU2002361659A patent/AU2002361659A1/en not_active Abandoned
- 2002-12-12 BR BRPI0215042-5A patent/BR0215042A/pt not_active IP Right Cessation
-
2004
- 2004-03-18 US US10/803,612 patent/US7067524B2/en not_active Expired - Fee Related
- 2004-07-12 ZA ZA200405512A patent/ZA200405512B/xx unknown
- 2004-07-12 NO NO20042955A patent/NO20042955L/no not_active Application Discontinuation
-
2007
- 2007-07-27 RU RU2007128958/04A patent/RU2007128958A/ru not_active Application Discontinuation
-
2009
- 2009-10-06 AU AU2009222567A patent/AU2009222567A1/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
PL374300A1 (en) | 2005-10-03 |
MXPA04005629A (es) | 2004-12-06 |
TW200300668A (en) | 2003-06-16 |
US20030181519A1 (en) | 2003-09-25 |
AR038019A1 (es) | 2004-12-22 |
IL161740A0 (en) | 2005-11-20 |
RU2314283C2 (ru) | 2008-01-10 |
AU2009222567A1 (en) | 2009-10-22 |
NO20042955L (no) | 2004-07-12 |
US6914074B2 (en) | 2005-07-05 |
ZA200405512B (en) | 2007-02-28 |
AU2002361659A1 (en) | 2003-06-30 |
JP4566561B2 (ja) | 2010-10-20 |
KR20040071197A (ko) | 2004-08-11 |
CA2470109A1 (en) | 2003-06-26 |
US7067524B2 (en) | 2006-06-27 |
WO2003051805A3 (en) | 2003-09-04 |
RU2004121227A (ru) | 2006-01-10 |
RU2007128958A (ru) | 2009-02-10 |
CN1738788A (zh) | 2006-02-22 |
US20040225123A1 (en) | 2004-11-11 |
WO2003051805A2 (en) | 2003-06-26 |
BR0215042A (pt) | 2006-06-06 |
CA2470109C (en) | 2010-12-21 |
JP2005538924A (ja) | 2005-12-22 |
TWI306450B (en) | 2009-02-21 |
EP1453782A2 (en) | 2004-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0501025A2 (en) | Substituted phenyl naphthalenes as estrogenic agents and their use | |
HK1068555A1 (en) | New formulations and use thereof | |
GB0021885D0 (en) | New use | |
GB0125088D0 (en) | New use | |
GB0021497D0 (en) | Compounds and their use | |
GB0006864D0 (en) | New use | |
GB0018887D0 (en) | Compound and their therapeutic use | |
AU1046702A (en) | New use | |
GB0004183D0 (en) | New use | |
GB0119920D0 (en) | New use | |
AU2002356679A8 (en) | Clusianon isomers and use thereof | |
GB0018248D0 (en) | New use | |
GB0123991D0 (en) | New therapeutic use | |
GB0027181D0 (en) | New use | |
GB0130704D0 (en) | New use | |
GB0217042D0 (en) | New use | |
GB0119822D0 (en) | New use | |
GB0117918D0 (en) | New use | |
GB0129834D0 (en) | New use | |
GB0117913D0 (en) | New use | |
GB0115989D0 (en) | New use | |
GB0115598D0 (en) | New use | |
GB0114008D0 (en) | New therapautic use | |
GB0112208D0 (en) | New use | |
GB0112207D0 (en) | New use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |